Avanos to be acquired for $1.27B
Avanos Medical agreed to be acquired by private‑equity firm American Industrial Partners for $1.27 billion, sending the target's shares sharply higher on the announcement. The deal was reported alongside commentary that this is the type of industrial, cash‑flow‑driven transaction typical in a tighter private‑capital market. (markets.financialcontent.com).
Avanos Medical agreed to sell itself to American Industrial Partners in a $1.272 billion cash deal that would take the medical-device maker private. (avanos.investorroom.com) Avanos shareholders are set to receive $25 a share in cash under the merger agreement the company signed on April 13 and announced on April 14. The buyer is acquiring the Alpharetta, Georgia, company through merger vehicles named A-AV Holdco I and A-AV MergerSub. (sec.gov) The $25 offer equals a 72.1% premium to Avanos’s April 13 closing price and an 82.8% premium to its 30-day volume-weighted average price through that date, the company said. Avanos shares surged after the announcement, with trade reports showing the stock near the offer price. (avanos.investorroom.com) (markets.financialcontent.com) Avanos makes products used in digestive health and pain management, two medical-device categories that hospitals and clinicians buy repeatedly rather than once. In its February 24 results release, the company said 2025 net sales rose 1.9% to $701.2 million. (stocktitan.net) (nasdaq.com) That operating profile helps explain the buyer. American Industrial Partners describes itself as an operationally oriented investor, and Avanos chief executive David Pacitti said the company had spent several years reshaping itself into a more focused medical-technology business. (avanos.investorroom.com) Avanos had already been narrowing its portfolio before the sale. Its 2025 annual report said the company combined commercial operations around Digestive Health and Pain Management and Recovery, sold its respiratory health business earlier, and bought Nexus Medical in 2025 to add vascular-access products. (stocktitan.net) The board unanimously approved the merger agreement and recommended that shareholders vote for it, according to the filing and the company’s announcement. The deal is expected to close in the second half of 2026, subject to shareholder approval and regulatory clearances. (sec.gov) (marketchameleon.com) If the transaction closes, Avanos will leave the New York Stock Exchange and operate as a private company under American Industrial Partners. For shareholders, the immediate question is simpler: whether $25 a share is the final stop after Tuesday’s jump. (sec.gov)
